Patients with chronic heart failure, a disabling, deadly disease that worsens as the heart gradually pumps less efficiently, are getting a much-needed new option with U.S. approval of a novel drug from Amgen Inc. Corlanor is the first medication in a dozen years for heart failure, which is becoming more common with obesity - and more people surviving heart attacks due to better treatments. Meanwhile, the Food and Drug Administration is reviewing another heart failure pill, from Novartis AG, and could approve it this summer.